Download PDF
Thromb Haemost 1988; 59(03): 404-411
DOI: 10.1055/s-0038-1647505
Original Article
Schattauer GmbH Stuttgart

Renal and Hepatic Handling of Endogenous Tissue-Type Plasminogen Activator (t-PA) and Its Inhibitor in Man

E J P Brommer
1   The Gaubius Institute TNO, Leiden, The Netherlands
,
F H M Derkx
2   The Dept. of Internal Medicine I, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
,
M A D H Schalekamp
2   The Dept. of Internal Medicine I, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
,
G Dooijewaard
1   The Gaubius Institute TNO, Leiden, The Netherlands
,
M M v d Klaauw
3   The Institute for Preventive Health Care (NIPG-TNO), Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 02 October 1987

Accepted after revision 20 January 1988

Publication Date:
29 June 2018 (online)

  PDF Download Permissions and Reprints

Abstract

In eight male patients with normal liver and kidney function fibrinolytic components were measured in arterial blood and in renal and hepatic vein blood, obtained during catheterization for analysis of hypertension. Blood samples were collected simultaneously from veins und corresponding arteries before and 5 minutes after the completion of intravenous injection of desmopressin (DDAVP), 0.4 μg/kg body weight over a 10 minute period.

DDAVP induced a rise in t-PA antigen and activity, and in von Willebrand factor, accompanied by a decrease in free PA-inhibitor level. We failed to detect a significant rise in plasma urokinase activity. The concentrations of fibrinogen, plasminogen, α2-antiplasmin, antithrombin III and coeruloplasmin did not change either.

Renal production of t-PA under basal conditions was inferred from a negative arterio-venous (A-V) difference in t-PA-activity and in t-PA-antigen levels but this could not be confirmed by orthogonal regression analysis of the same data. A-V differences of other fibrinolytic factors were negligible.

In the hepatic vessels a significant positive A-V difference of t-PA-activity and of t-PA-antigen levels was a uniform finding. After DDAVP, when plasma levels were elevated, the mean A-V difference was proportionally higher, consistent with a constant fractional elimination rate. Free PA-inhibitor was virtually absent from arterial blood after DDAVP, but appeared in hepatic vein blood, indicating either production of the inhibitor by the liver or dissociation of a circulating complex of t-PA and its inhibitor in the liver. The blood levels of the other investigated components did not show any change upon passage through the liver. Plotting of individual venous versus arterial levels of t-PA activity and of t-PA-antigen both before and after DDAVP injection yielded straight lines which in orthogonal regression analysis showed a slope significantly lower than unity; this was interpreted as net clearance of the activator. Clearance rate was not changed by DDAVP. Assuming a normal blood volume and hepatic blood flow in these subjects, the t½ of the disappearance of endogenous plasminogen activator over the liver can be calculated: t-PA-activity: 3.1 min, t-PA-antigen: 4.1 min. Since these figures are close to those found by others for the halfdisappearance time of t-PA from the entire circulation, it is concluded that t-PA is eliminated from the blood mainly by the liver. The t½ of disappearance of endogenous, free PA-inhibitor is about 3 times longer, in our example 10.4 minutes.

Keywords

t-PA - PAI - DDAVP - Clearance
 

  • References

  • 1 Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Sem Thromb Haemostas 1984; 10: 24-41
    PubMedGoogle Scholar
  • 2 Mannucci PM, Forman SP. Hemostasis and thrombosis. In Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (Eds) Lippinccott Company; Philadelphia - Toronto: 1982: 595-601
    Google Scholar
  • 3 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
    PubMedGoogle Scholar
  • 4 Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-544
    PubMedGoogle Scholar
  • 5 Nilsson S, Einarsson M, Ekvärn S. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 1985; 39: 511-521
    CrossrefPubMedGoogle Scholar
  • 6 Bounameaux H, Verstraete M, Collen D. Pharmacokinetics of human tissue-type plasminogen activator (t-PA). In Thrombolysis. Collen D, Lijnen HR, Verstraete M. (Eds) Churchill Livingstone; Edinburgh: 1985: 85-91
    Google Scholar
  • 7 Brommer EJ P, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemostas 1984; 52: 311-314
    PubMedGoogle Scholar
  • 8 Januszko T, Furman M, Buluk K. The kidneys and the liver as the organs regulating the fibrinolytic system of the circulating blood. Thromb Diath Haemorrh 1966; 15: 554-560
    PubMedGoogle Scholar
  • 9 Bulukj K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia 1962; 18: 146-147
    CrossrefPubMedGoogle Scholar
  • 10 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood in dog. Thromb Diath Haemorrh 1964; 12: 87-104
    PubMedGoogle Scholar
  • 11 Brakman P, Astrup T. Increased fibrinolytic activity in venous blood from the kidneys. Fed Proc 1965; 24: 387 (Abstr)
    PubMedGoogle Scholar
  • 12 Holemans R, Mann LS, Cope C. Fibrinolytic activity of renal venous and arterial blood. Am J Med Sci 1967; 254: 330-333
    CrossrefPubMedGoogle Scholar
  • 13 Menon IS, Dewar HA, Newell DJ. Role of the kidney in fibrinolytic activity of blood. Lancet 1968; 1: 785-788
    PubMedGoogle Scholar
  • 14 Schrader J, Neuhaus KL, Tebbe U, Köstering H, Scheler F. Fibrinolytic activity in renal venous blood in man. Klin Wochenschr 1986; 64: 587-589
    CrossrefPubMedGoogle Scholar
  • 15 Bergstein JM, Kuederli U, Bang NU. Plasma inhibitor of glomerular fibrinolysis in the hemolytic-uremic syndrome. Am J Med 1982; 73: 322-327
    CrossrefPubMedGoogle Scholar
  • 16 Derkx FM, Man In’t Veld AJ, Jones R, Reid JL, Schalekamp MA D H. DDAVP (1-desamino-8-D-arginine vasopreśsin): an antagonist of the pressor action of endogenous vasopressin. J Hypertension 1983; 1: 58-61
    PubMedGoogle Scholar
  • 17 Derkx FH M, Brommer EJ P, Boomsma F, Schalekamp MA D H. Activation of plasma prorenin by plasminogen activators in vitro and increase in plasma renin after stimulation of fibrinolytic activity in vivo. Neth J Med 1984; 27: 124-128
    PubMedGoogle Scholar
  • 18 Rijken DC, Van Hinsbergh VW M, Sens EH C. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 1984; 33: 145-153
    CrossrefPubMedGoogle Scholar
  • 19 Kluft C. C1inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135-151
    CrossrefPubMedGoogle Scholar
  • 20 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 21 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
    PubMedGoogle Scholar
  • 22 Kluft C, Wijngaards G, Jie AF H. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. 1984; J Lab Clin Med 1984; 103: 408-419
    PubMedGoogle Scholar
  • 23 Kluft C, Jie AF H, Allen RA. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemostas 1983; 50: 518-523
    PubMedGoogle Scholar
  • 24 Brommer EJ P, Barrett-Bergshoeff MM, Allan RA, Schicht I, Bertina RM, Schalekamp MA D H. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients - Analysis of responders and non-responders. Thromb Haemostas 1982; 48: 156-161
    PubMedGoogle Scholar
  • 25 Van der Velde EA. Orthogonal regression equation. In Thromboplastin Calibration and Oral Anticoagulant Control. Van den Besselaar AM H P, Gralnick HR, Lewis SM. (Eds) Martinus, Nijhoff; The Hague: 1984: 25-39
    Google Scholar
  • 26 Ganong WF. Review of Medical Physiology. Lange Medical Publications; Los Altos: 1981
    Google Scholar
  • 27 Nilsson T, Wallen P, Nellbring G. In vivo metabolism of human tissue- type plasminogen activator. Scand J Haematol 1984; 33: 49-53
    PubMedGoogle Scholar
  • 28 Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel BE, Jaffe AS. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemostas 1987; 57: 35-40
    PubMedGoogle Scholar
  • 29 Verstraete M, Su CA P F, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulant parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostas 1986; 56: 1-5
    PubMedGoogle Scholar
  • 30 Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, Kanke M, Collen D. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardial 1987; 9: 599-607
    CrossrefPubMedGoogle Scholar
  • 31 Brommer EJ P, Verheijen JH, Chang GT G, Rijken DC. Masking of the fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemostas 1984; 52: 154-156
    PubMedGoogle Scholar
  • 32 Loskutoff DJ, Edgington TS. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 1981; 256: 4142-4145
    PubMedGoogle Scholar
  • 33 Emeis JJ, Van Hinsbergh VW M, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun 1983; 110: 392-398
    CrossrefPubMedGoogle Scholar
  • 34 Philips M, Juli A-G, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Acta 1984; 802: 99-110
    PubMedGoogle Scholar
  • 35 Sprengers ED, Princen HM G, Kooistra T, Van Hinsbergh VW M. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758
    PubMedGoogle Scholar
  • 36 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 37 Kruithof EK O, Ransijn A. Bachmann E Inhibition of tissue plasminogen activator by human plasma. In Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. Churchill Livingstone; Edinburgh: 1983. 6 365-369
    Google Scholar
  • 38 Emeis JJ, Van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemostas 1985; 54: 661-664
    PubMedGoogle Scholar
  • 39 Stibbe J, Kluft C, Brommer EJ P, Gomes M, De Jong DS, Nauta J. Secretion of extrinsic (tissue-type) plasminogen activator by endothelial cells is the cause of enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery. Eur J Clin Invest 1984; 14: 375-382
    CrossrefPubMedGoogle Scholar
  • 40 Menon IS, Muscat-Baron J, Dewar HA. Comparison of fibrinolytic activity in hepatic and systemic venous blood. J Atheroscler Res 1968; 8: 547-554
    CrossrefPubMedGoogle Scholar
  • 41 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
    CrossrefPubMedGoogle Scholar
  • 42 Kwaan HC, McFadzean AJ S, Cook J. On plasma fibrinolytic activity in cryptogenic splenomegaly. Scot Med J 1957; 2: 137-150
    PubMedGoogle Scholar
  • 43 Prentice CR M, Hassanein AA, McNicol GP, Douglas AS. Studies on blood coagulation, fibrinolysis and platelet function following exercise in normal and splenectomized people. Br J Haematol 1972; 23: 541-552
    CrossrefPubMedGoogle Scholar
  • 44 Leevy CM, Bender J, Silverberg M. Naylor. Physiology of dye extraction by the liver: comparative study of sulfobromophthalein and indocyanine green. Am New York Acad Sci 1963; 111: 161-175
    PubMedGoogle Scholar
  • 45 Pirttiaho H, Pitkanen U, Rajasalmi M, Ahonen A. Comparison of three methods of measuring liver blood flow. Acta Radiol Diagn 1980; 21: 535-539
    PubMedGoogle Scholar
  • 46 Deykin D. The role of the liver in serum-induced hypercoagulability. J Clin Invest 1966; 45: 256-263
    CrossrefPubMedGoogle Scholar
  • 47 Gans H, Lowman JT. The uptake of fibrin and fibrin-degradation products by the isolated perfused rat liver. Blood 1967; 29: 526-539
    PubMedGoogle Scholar
  • 48 Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. J Clin Invest 1964; 43: 681-695
    CrossrefPubMedGoogle Scholar
  • 49 Weiner M. The fibrinolytic response to nicotinic acid in abnormal liver states. Am J Med Sci 1963; 246: 294-300
    CrossrefPubMedGoogle Scholar
  • 50 Tytgat G, Collen D, De Vreker R, Verstraete M. Investigations on the fibrinolytic system in liver cirrhosis. Acta Haematol 1968; 40: 265-274
    CrossrefPubMedGoogle Scholar
  • 51 Das PC, Cash JD. Fibrinolysis at rest and after exercise in hepatic cirrhosis. Br J Haematol 1969; 17: 431-443
    CrossrefPubMedGoogle Scholar
  • 52 Brommer EJ P. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis. Inefficiency of t-PA added afterwards Thromb Res 1984; 34: 109-115
    CrossrefPubMedGoogle Scholar
  • 53 Mannucci PM, Åberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93
    CrossrefPubMedGoogle Scholar